This report examines the BLOCKING Act and why it is a misguided attempt at promoting generic drug competition.
In anticipation of the December jobs report number being released later in the morning, Brill joins the morning news program to discuss his predictions that the number “will be right on the quarterly trend.”
“I advocate and support a carbon tax, but not just blindly, not just any carbon tax. It is critically important that the carbon tax be revenue neutral. That at the time at which this policy is put in place its done in a matter in which the revenues expected to be generated from the carbon tax are used to reduce other taxes that are more distortionary. This is what we would call the principles of basic tax reform.”
Alex Brill was quoted in Fast Company for his research on tax policy effects on business:
“… [Brill] has found that employees in ESOPs “get better at the job, and instead of quitting as soon as they get skills, they stay and get more skills.” Companies with ESOPs require fewer managers, as AEI’s Brill discovered in his research, because workers are given more freedom and are better able to manage themselves.”
Is the tax code sufficiently progressive? The answer depends not only on the values of the person answering the question, but it also is a surprisingly tricky empirical exercise. What counts as income and who pays the corporate tax? How should one measure households?
There is currently a debate among policy analysts and commentators about whether the Tax Cuts and Jobs Act of 2017 (TCJA) was “pro-family.”
There is a hot debate in many countries over youth use of e-cigarettes, electronic devices that deliver nicotine to consumers without the deadly tar found in the smoke from traditional cigarettes. Although nicotine is not a carcinogen, it is still bad for developing brains and should not be used by young adults or pregnant women. At the same time, e-cigarettes offer real advantages over traditional tobacco products for smokers who are otherwise unable to quit.
“A new report from Matrix Global Advisors and the National Business Group on Health, sponsored by Boehringer Ingelheim, shows that employers could see substantial savings from biosimilars, but those savings won’t come without a concerted effort to encourage biosimilar use.”
This paper estimates the savings opportunity from biosimilars in the medical benefit of a large employer-sponsored health plan, using real-world claims data. This analysis illustrates the savings potential of biosimilars in the commercial market and highlights the important role of employer-sponsored plans in promoting biosimilar utilization.